Hyundai Bioscience announced that CNPharm, its major shareholding bio tech company, has succeeded in developing 'Poly-COV01,' an injection drug for the potential treatment of patients with severe cases of Covid-19.
Pharmaceutical company Servier has agreed to acquire oncology business from Agios Pharmaceuticals for up to $2bn.
Neurogene, a company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the completion of a $115m Series B financing.
Swiss drugmaker Novartis has agreed to acquire US-based neuroscience company Cadent Therapeutics for a total potential consideration of $770m.
CN Bio announced a collaboration with the University of Melbourne, focused on respiratory therapies for recovering COVID-19 patients.
Eli Lilly has agreed to acquire US-based gene therapy company Prevail Therapeutics for an aggregate value of up to $1.04bn.
Eureka Therapeutics announced successful preclinical results from its InvisiMask Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.
Private investment organisation EQT IX has offered to acquire Swedish contract development and manufacturing organisation (CDMO) Recipharm for $2.1bn.
AstraZeneca has agreed to acquire US-based biopharmaceutical company Alexion Pharmaceuticals in a deal valued at $39bn.
Gilead Sciences and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for the treatment of chronic hepatitis delta virus (HDV), have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 billion in cash.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.